Market Research

Peptide Drug Conjugates Market Size, Share & Trends Analysis Report By Product (Illuccix, Pluvicto, CBX-12, Pipeline Products), By Type (Diagnostic, Therapeutic), By Region, And Segment Forecasts, 2025 - 2030

Best Price Guarantee Length Publisher Published Date SKU
from $5,950 100 Pages Grand View Research February, 2025 GV19793450
Best Price Guarantee
Price from $5,950
Length 100 Pages
Publisher Grand View Research
Published Date February, 2025
SKU GV19793450

Peptide Drug Conjugates Market Growth & Trends

The global peptide drug conjugates market size is estimated to reach USD 12.84 billion by 2030, registering to grow at a CAGR of 19.21% from 2025 to 2030 according to a new report by Grand View Research, Inc. The growth of market is attributed to the global upsurge in cancer cases and related mortality, strong clinical trial pipeline with peptide drug conjugates (PDCs) and associated side effects of the existing products such as uncontrolled toxicity associated with small molecule chemotherapeutic agents.

According to WHO, cancer is the leading cause of disease related deaths, worldwide. In 2020, around 10.0 million deaths globally and more than 6.0 million deaths in the U.S. were recorded due to the cancer. Furthermore, as per cancer.gov, by 2040, the new cancer cases patients per year is estimated to reach to 29.0 million and the number of cancer-related deaths to 16.0 million. Therefore, rising demand for the novel treatment like PDCs to target uncontrolled cell growth is expected to fuel the peptide drug conjugates market growth.

Currently, Lutathera (Lu 177 dotatate) and Pepaxto (Melflufen) are the two FDA approved PDCs to treat uncontrolled cell growth. The marketplace has the FDA approved PDC as the Novartis’s Lutathera (lutetium Lu 177)indicated for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors in adults. Later, in February 2021, Oncopeptides ABs announced the FDA’s accelerated approval for Pepaxto (Melphalan) indicated for the treatment in multiple myeloma. Presence of limited PDCs in space in offering remunerative opportunity for the growth.

Furthermore, presence of robust clinical trial pipeline and expected launch of new PDCs is anticipated to boost the market growth during the forecast period. These can attribute due to the PDC ANG1005 under phase 3 clinical studies for brain tumor, and PDCs BT5528 and BT1718 under phase 2 to clinical studies for lung cancer. CBX-12 is another phase 2 PDC candidate indicated for the small cell lung cancer treatment.

Key players are undertaking strategic initiatives such as collaborations, merger & acquisitions, agreements, along with financial investments, which is driving the market growth. For instance, in December 2021, Coherent Biopharma and WuXi STA announced the strategic partnership agreement to develop their current and future therapeutic drugs including peptide drug conjugates.

Peptide Drug Conjugates Market Report Highlights

  • The therapeutic segment dominated the industry in 2024 and is anticipated to witness the fastest growth.
  • The pluvicto segment dominated the industry with a revenue share of 42.52% in 2024 and is expected to exhibit the fastest CAGR over the forecast period.
  • North America peptide drug conjugates market held a leading position in 2024, accounting for 75.02% of the global share.
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Peptide Drug Conjugates Market Variables, Trends, & Scope
3.1. Parent Market Outlook
3.2. Ancillary Market Outlook
3.3. Market Dynamics
3.3.1. Market drivers analysis
3.3.1.1. Rising prevalence of neurological disorders increasing disease prevalence
3.3.1.2. Robust clinical trial pipeline
3.3.1.3. Growing focus on targeted drug delivery
3.3.2. Market Restraints Analysis
3.3.2.1. Long R&D time and slow clinical development process
3.3.2.2. Stringent regulations associated with peptide drug conjugates (PDC’s)
3.4. Dopamine Agonist Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
3.5. Pipeline Analysis
3.5.1. Phase 1
3.5.2. Phase 2
3.5.3. Phase 3
Chapter 4. Peptide Drug Conjugates Market: By Product Estimates & Trend Analysis
4.1. Peptide Drug Conjugates Market: Product Segment Dashboard
4.2. Peptide Drug Conjugates Market: By Product Movement Analysis, 2024 & 2030 (USD Million)
4.3. Illuccix
4.3.1. Illuccix Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Pluvicto
4.4.1. Pluvicto Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Lutathera
4.5.1. Lutathera Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. OctreoScan
4.6.1. OctreoScan Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Others
4.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Peptide Drug Conjugates Market: Type Estimates & Trend Analysis
5.1. Peptide Drug Conjugates Market: Type Segment Dashboard
5.2. Peptide Drug Conjugates Market: By Type Movement Analysis, 2024 & 2030 (USD Million)
5.3. Therapeutics
5.3.1. Therapeutics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Diagnostics
5.4.1. Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Peptide Drug Conjugates Market: Regional Estimates & Trend Analysis
6.1. Peptide Drug Conjugates Market Share, By Region, 2024 & 2030, USD Million
6.2. North America
6.2.1. North America Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.2. U.S.
6.2.2.1. Key Country Dynamics
6.2.2.2. Target Disease Prevalence
6.2.2.3. Regulatory Framework
6.2.2.4. Reimbursement Framework
6.2.2.5. U.S. Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.3. Canada
6.2.3.1. Key Country Dynamics
6.2.3.2. Target Disease Prevalence
6.2.3.3. Regulatory Framework
6.2.3.4. Reimbursement Framework
6.2.3.5. Canada Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.4. Mexico
6.2.4.1. Key Country Dynamics
6.2.4.2. Target Disease Prevalence
6.2.4.3. Regulatory Framework
6.2.4.4. Reimbursement Framework
6.2.4.5. Mexico Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3. Europe
6.3.1. Europe Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.2. UK
6.3.2.1. Key Country Dynamics
6.3.2.2. Target Disease Prevalence
6.3.2.3. Regulatory Framework
6.3.2.4. Reimbursement Framework
6.3.2.5. Uk Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.3. Germany
6.3.3.1. Key Country Dynamics
6.3.3.2. Target Disease Prevalence
6.3.3.3. Regulatory Framework
6.3.3.4. Reimbursement Framework
6.3.3.5. Germany Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.4. France
6.3.4.1. Key Country Dynamics
6.3.4.2. Target Disease Prevalence
6.3.4.3. Regulatory Framework
6.3.4.4. Reimbursement Framework
6.3.4.5. France Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.5. Italy
6.3.5.1. Key Country Dynamics
6.3.5.2. Target Disease Prevalence
6.3.5.3. Regulatory Framework
6.3.5.4. Reimbursement Framework
6.3.5.5. Italy Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.6. Spain
6.3.6.1. Key Country Dynamics
6.3.6.2. Target Disease Prevalence
6.3.6.3. Regulatory Framework
6.3.6.4. Reimbursement Framework
6.3.6.5. Spain Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.7. Denmark
6.3.7.1. Key Country Dynamics
6.3.7.2. Target Disease Prevalence
6.3.7.3. Regulatory Framework
6.3.7.4. Reimbursement Framework
6.3.7.5. Denmark Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.8. Sweden
6.3.8.1. Key Country Dynamics
6.3.8.2. Target Disease Prevalence
6.3.8.3. Regulatory Framework
6.3.8.4. Reimbursement Framework
6.3.8.5. Sweden Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.9. Norway
6.3.9.1. Key Country Dynamics
6.3.9.2. Target Disease Prevalence
6.3.9.3. Regulatory Framework
6.3.9.4. Reimbursement Framework
6.3.9.5. Norway Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Asia Pacific
6.4.1. Asia Pacific Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.2. Japan
6.4.2.1. Key Country Dynamics
6.4.2.2. Target Disease Prevalence
6.4.2.3. Regulatory Framework
6.4.2.4. Reimbursement Framework
6.4.2.5. Japan Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.3. China
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. Regulatory Framework
6.4.3.4. Reimbursement Framework
6.4.3.5. China Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.4. India
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. Regulatory Framework
6.4.4.4. Reimbursement Framework
6.4.4.5. India Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.5. Australia
6.4.5.1. Key Country Dynamics
6.4.5.2. Target Disease Prevalence
6.4.5.3. Regulatory Framework
6.4.5.4. Reimbursement Framework
6.4.5.5. Australia Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.6. South Korea
6.4.6.1. Key Country Dynamics
6.4.6.2. Target Disease Prevalence
6.4.6.3. Regulatory Framework
6.4.6.4. Reimbursement Framework
6.4.6.5. South Korea Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.7. Thailand
6.4.7.1. Key Country Dynamics
6.4.7.2. Target Disease Prevalence
6.4.7.3. Regulatory Framework
6.4.7.4. Reimbursement Framework
6.4.7.5. Thailand Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Latin America
6.5.1. Latin America Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.2. Brazil
6.5.2.1. Key Country Dynamics
6.5.2.2. Target Disease Prevalence
6.5.2.3. Regulatory Framework
6.5.2.4. Reimbursement Framework
6.5.2.5. Japan Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.3. Argentina
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Regulatory Framework
6.5.3.4. Reimbursement Framework
6.5.3.5. China Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Middle East and Africa
6.6.1. Middle East and Africa Peptide Drug Conjugates Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.6.2. South Africa
6.6.2.1. Key Country Dynamics
6.6.2.2. Target Disease Prevalence
6.6.2.3. Regulatory Framework
6.6.2.4. Reimbursement Framework
6.6.2.5. South Africa Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.3. Saudi Arabia
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Regulatory Framework
6.6.3.4. Reimbursement Framework
6.6.3.5. Saudi Arabia Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.4. UAE
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Prevalence
6.6.4.3. Regulatory Framework
6.6.4.4. Reimbursement Framework
6.6.4.5. UAE Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.5. Kuwait
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Prevalence
6.6.5.3. Regulatory Framework
6.6.5.4. Reimbursement Framework
6.6.5.5. Kuwait Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis by Key Market Participants
7.2. Company Categorization
7.3. Participant Overview
7.4. Financial Performance
7.5. Product Bench Marking
7.6. Company Market Share Analysis, 2024
7.7. Company Profiles
7.7.1. Novartis AG
7.7.1.1. Participant’s Overview
7.7.1.2. Financial Performance
7.7.1.3. Product Benchmarking
7.7.1.4. Recent Developments/ Strategic Initiatives
7.7.2. AstraZeneca
7.7.2.1. Participant’s Overview
7.7.2.2. Financial Performance
7.7.2.3. Product Benchmarking
7.7.2.4. Recent Developments/ Strategic Initiatives
7.7.3. Oncopeptides AB
7.7.3.1. Participant’s Overview
7.7.3.2. Financial Performance
7.7.3.3. Product Benchmarking
7.7.3.4. Recent Developments/ Strategic Initiatives
7.7.4. Bicycle Therapeutics
7.7.4.1. Participant’s Overview
7.7.4.2. Financial Performance
7.7.4.3. Product Benchmarking
7.7.4.4. Recent Developments/ Strategic Initiatives
7.7.5. Cybrexa
7.7.5.1. Participant’s Overview
7.7.5.2. Financial Performance
7.7.5.3. Product Benchmarking
7.7.5.4. Recent Developments/ Strategic Initiatives
7.7.6. Angiochem Inc.
7.7.6.1. Participant’s Overview
7.7.6.2. Financial Performance
7.7.6.3. Product Benchmarking
7.7.6.4. Recent Developments/ Strategic Initiatives
7.7.7. Soricimed Biopharma
7.7.7.1. Participant’s Overview
7.7.7.2. Financial Performance
7.7.7.3. Product Benchmarking
7.7.7.4. Recent Developments/ Strategic Initiatives
7.7.8. Theratechnologies Inc.
7.7.8.1. Participant’s Overview
7.7.8.2. Financial Performance
7.7.8.3. Product Benchmarking
7.7.8.4. Recent Developments/ Strategic Initiatives
Chapter 8. Conclusion

$5,950
$6,950
$8,950

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings